Drug doubles survival in pancreatic cancer, Nature Briefing roundup

A drug trial report shows that the experimental drug daraxonrasib nearly doubled median survival in people with advanced pancreatic cancer.

• Main announcement: daraxonrasib targets all three RAS proteins and in a trial of 500 people with advanced pancreatic cancer patients who received the drug lived 13.2 months versus 6.7 months for chemotherapy; results reported in the New England Journal of Medicine (DOI: 10.1056/NEJMoa2605555).
• Background and other details: The Nature Briefing compiles other verifiable items in the issue, including a federal judge blocking the Trump administration’s move to transfer NCAR’s supercomputing center in Wyoming (ruling calls the action “capricious, an abuse of discretion, or otherwise not in accordance with law”), concerns about AI in social sciences, warnings on Ebola preparedness by Kevin Ariën, and conservation work at Kew/Millennium Seed Bank (29 seeds collected, 8 germinated).